Original Research ARTICLE
Peptidylarginine Deiminase Inhibitor Suppresses Neutrophil Extracellular Trap Formation and MPO-ANCA Production
- 1Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
- 2Faculty of Health Sciences, Hokkaido University, Sapporo, Japan
- 3Department of Pathology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA)-associated vasculitis is a systemic small-vessel vasculitis, wherein, MPO-ANCA plays a critical role in the pathogenesis. Neutrophil extracellular traps (NETs) released from activated neutrophils are composed of extracellular web-like DNA and antimicrobial proteins, including MPO. Diverse stimuli, such as phorbol myristate acetate (PMA) and ligands of toll-like receptors (TLR), induce NETs. Although TLR-mediated NET formation can occur with preservation of living neutrophilic functions (called vital NETosis), PMA-stimulated neutrophils undergo cell death with NET formation (called suicidal NETosis). In the process of suicidal NETosis, histones are citrullinated by peptidylarginine deiminase 4 (PAD4). Since this step is necessary for decondensation of DNA, PAD4 plays a pivotal role in suicidal NETosis. Although NETs are essential for elimination of microorganisms, excessive formation of NETs has been suggested to be implicated in MPO-ANCA production. This study aimed to determine if pan-PAD inhibitors could suppress MPO-ANCA production in vivo. At first, NETs were induced in peripheral blood neutrophils derived from healthy donors (1 × 106/ml) by stimulation with 20 nM PMA with or without 20 μM propylthiouracil (PTU), an anti-thyroid drug. We then determined that the in vitro NET formation was inhibited completely by 200 μM Cl-amidine, a pan-PAD inhibitor. Next, we established mouse models with MPO-ANCA production. BALB/c mice were given intraperitoneal (i.p.) injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day) for 2 weeks. These mice were divided into two groups; the first group was given daily i.p. injection of PBS (200 μl/day) (n = 13) and the other group with daily i.p. injection of Cl-amidine (0.3 mg/200 μl PBS/day) (n = 7). Two weeks later, citrullination as an indicator of NET formation in the peritoneum and serum MPO-ANCA titer was compared between the two groups. Results demonstrated that citrullination in the peritoneum was significantly reduced in the Cl-amidine-treated mice compared with the vehicle-injected control mice (38% reduction). Additionally, the serum MPO-ANCA titer of the Cl-amidine-treated mice (32.3 ± 31.0 ng/ml) was significantly lower than that in the vehicle-injected mice (132.1 ± 41.6 ng/ml). The collective findings indicate that excessive formation of NETs may be implicated in MPO-ANCA production in vivo.
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis is a systemic small-vessel vasculitis (1). The major target antigens of ANCA are myeloperoxidase (MPO) and proteinase 3 (PR3). Neutrophils primed by pro-inflammatory cytokines, such as TNF-α, express MPO and PR3 on the cell surface. ANCA bind to the antigens and then activate neutrophils directly and/or through binding to bystander Fcγ receptors. Consequently, the activated neutrophils induce vascular endothelial cell injury resulting in the development of small-vessel vasculitis (2, 3). ANCA, therefore, play a critical role in the pathogenesis of ANCA-associated vasculitis. Although the mechanism of MPO-ANCA production was unknown for a long time, recent studies have suggested the involvement of neutrophil extracellular traps (NETs) in the mechanism (4–6).
Neutrophil extracellular traps are firstly reported in 2004 as extracellular web-like DNA studded with antimicrobial proteins, including MPO, which are released from phorbol myristate acetate (PMA)-stimulated neutrophils (7). The PMA-stimulated neutrophils undergo cell death with the formation of NETs (8), though not all stimuli induce cell death in NET-forming neutrophil (9). It has been demonstrated that NET formation can occur with preservation of living neutrophilic functions, including phagocytosis and chemotaxis (10, 11). Currently, NET formation undergoing cell death is called suicidal NETosis, whereas that preserves living neutrophilic functions is called vital NETosis. NETs can trap microorganisms by the extracellular DNA and kill them using the antimicrobial proteins. Thus, NETosis is considered as an important event in innate immunity. However, excessive NETosis can result in vascular endothelial cell injury (12), thrombosis (13, 14), and impairment of diabetic wound healing (15, 16). In addition, disordered regulation of NETosis has been suggested to be involved in the pathogenesis of autoimmune diseases, including systemic lupus erythematosus (SLE) (17) and anti-thyroid drug propylthiouracil (PTU)-induced MPO-ANCA-associated vasculitis (5). In the last two studies, the possibility of extracellular components in persistent NETs recognized as autoantigens by the immune system was discussed.
Suicidal NETosis is induced in response to diverse stimuli, including PMA (7, 18). These stimuli activate the Raf–mitogen-activated protein kinase kinase–extracellular signal-regulated kinase pathway, NADPH oxidase-dependent production of reactive oxygen species, and receptor-interacting protein kinase/mixed lineage kinase domain-like-mediated signals (19, 20). In this pathway, peptidylarginine deiminase 4 (PAD4) yields citrullination of histones, around which DNA coils.
The PAD enzymes convert arginine residues to citrulline in a variety of protein substrates (21). Among the PAD family, which includes PAD 1–4 and 6, PAD4 is expressed mainly in hematopoietic cells, such as neutrophils (22). In the process of suicidal NETosis, PAD4-dependent citrullination of histones that yields decondensation of DNA is an essential step to mix DNA and intracytoplasmic proteins. This mixture is subsequently extruded from the ruptured plasma membrane. Accordingly, PAD4 plays a pivotal role in the process of suicidal NETosis (23).
In the present study, we aimed to determine if a pan-PAD inhibitor, Cl-amidine, could suppress MPO-ANCA production in vivo. For this purpose, we attempted to generate novel mouse models of MPO-ANCA-associated vasculitis according to our previous protocol utilized for establishment of a rat model of this disease (5). The mouse models would be more useful models that require lower doses of reagents than the rat model.
Materials and Methods
Human Neutrophil Isolation
Human peripheral blood neutrophils were obtained from healthy volunteers by density centrifugation using Polymorphprep (Axis-Shield, Dundee, Scotland) according to the manufacturer’s instructions.
NET Induction In Vitro
The in vitro NET induction was conducted similarly to our earlier study (5). In brief, human peripheral blood neutrophils were re-suspended in RPMI 1640 medium supplemented with 5% fetal bovine serum and then seeded in wells of 4-well chamber slides (Thermo Fisher Scientific, Yokohama, Japan) (1 × 106/ml). After incubation for 30 min at 37°C, the cells were exposed to 0 or 20 nM PMA (Sigma-Aldrich, St. Louis, MO, USA) with or without 20 μM PTU (Chugai Pharmaceutical, Tokyo, Japan) and incubated for another 2 h at 37°C.
PAD Inhibitor Administration In Vitro
Fifteen minutes prior to the PMA/PTU administration, 200 μM Cl-amidine (Calbiochem, San Diego, CA, USA), a pan-PAD inhibitor, was added alternately into the wells. The concentration of Cl-amidine was adopted according to the previous report (24).
Quantification of NETs In Vitro
After 2 h of incubation, the medium containing the reagents was removed, and the remaining cells were washed with PBS followed by fixation with 4% paraformaldehyde for 15 min. Thereafter, the specimens were made to react with 5 μg/ml of rabbit anti-human citrullinated histone 3 polyclonal antibody (Abcam, Cambridge, UK) for 60 min at room temperature. After removal of unbound antibody, the specimens were next allowed to react with 1:500 dilution of Alexa Fluor 594-conjugated goat anti-rabbit IgG antibody (Invitrogen, Tokyo, Japan) for 60 min at room temperature. After washing with PBS, the specimens were finally mounted with the 4′, 6-diamidino-2-phenylindole (DAPI)-containing solution (Sigma-Aldrich). NET formation was observed under a fluorescent microscope and was quantified by counting the citrullinated histone 3-positive cells per × 100 power field of view. Data from five random fields of view (×100) were subjected to the quantitative analysis.
Establishment of Mouse Models with MPO-ANCA Production
BALB/c, New Zealand White (NZW), C57BL/6N (B6/N), C57BL/6J (B6/J), and DBA mice (14-week-old female) were purchased from Clea Japan (Tokyo, Japan). The mice were given intraperitoneal (i.p.) injection of PMA (50 ng at days 0 and 7) and oral administration of PTU dissolved in 5% glucose water for 4 weeks (n = 5/strain). Since preliminary experiments revealed that each mouse ingested at least 2.5 ml of the drug-containing glucose water, the concentration of PTU was set as 1 mg/ml in order to administer exactly 2.5 mg PTU per day. These mice were maintained under specific pathogen-free condition in accordance with the guidelines for the care and use of laboratory animals in Hokkaido University (Permission No. 12-0077).
Mouse urine was collected during the last 24 h using metabolic cages. Blood samples were obtained at days 14 and 28. Hematuria was assessed by dipsticks (Siemens Healthcare, Tokyo, Japan). Biochemical examinations for blood nitrogen urea (BUN) and creatinine (Cr) were performed at Daiichi Kishimoto Clinical Laboratory (Sapporo, Japan). Serum titer of MPO-ANCA was determined by enzyme-linked immunosorbent assay (ELISA) at A-CLIP Institute (Chiba, Japan).
The lungs, kidneys, and peritoneal tissues were obtained at day 28 and then fixed in 10% formalin. The pulmonary and renal sections were subjected to hematoxylin and eosin staining. The sections of the peritoneal tissues were subjected to immunohistochemistry for citrullinated histone 3 as described previously (25, 26).
PAD Inhibitor Administration In Vivo
BALB/c mice (14-week-old female) were given i.p. injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day, aforementioned protocol) for 2 weeks. These mice were divided into two groups. The first group was given daily i.p. injection of PBS (200 μl/day) (n = 13). The second group was given daily i.p. injection of Cl-amidine (0.3 mg/200 μl PBS/day) (n = 7). The dose of Cl-amidine was adopted according to the previous report (27). Each mouse was administered at least 10 mg/kg of Cl-amidine per day. Mouse urine was collected during the last 24 h using metabolic cages. Blood and tissue samples were obtained at day 14.
The in vitro data were presented as mean ± standard deviation (SD) values obtained from experiments repeated for at least five times. The in vivo data were also presented as mean ± SD values. Mann–Whitney U-tests were applied for statistical evaluation with StatPlus software. P-values of <0.05 were regarded as statistically significant.
Effect of PAD Inhibitor on NET Induction In Vitro
Human peripheral blood neutrophils were exposed to 0 or 20 nM PMA with or without 20 μM PTU. Fifteen minutes prior to PMA/PTU exposure, the neutrophils were treated with or without 200 μM Cl-amidine. Stimulation without PMA did not induce NETs (data not shown). It has been also determined that 200 μM of Cl-amidine did not affect the viability of neutrophils in vitro (Figure S1 in Supplementary Material).
The neutrophils stimulated by 20 nM PMA alone formed extended NETs, whereas neutrophils stimulated by 20 nM PMA plus 20 μM PTU formed non-extended round-shaped NETs (Figure 1A). These findings corresponded with our earlier observations (5) and suggested that PTU yielded abnormal conformation of NETs induced by PMA. Although the morphology of NETs was different, both stimuli (PMA alone and PMA plus PTU) were shown to induce citrullination of histone 3 (5). Therefore, PAD4 was likely involved in the NET induction by these stimuli. As expected, the pan-PAD inhibitor, Cl-amidine (200 μM) inhibited the NET formation induced by both PMA alone and PMA plus PTU in vitro (Figures 1A,B). Furthermore, these findings suggest that Cl-amidine can inhibit not only the formation of PMA-induced conventional (extended) NETs but also PTU-mediated unconventional (non-extended round-shaped) NETs.
Figure 1. Effect of Cl-amidine on NET induction in vitro. Human peripheral blood neutrophils were seeded in wells of 4-well chamber slides (1 × 106/ml). After incubation for 30 min at 37°C, the cells were exposed to 0 or 20 nM PMA with or without 20 μM PTU. Fifteen minutes prior to PMA/PTU administration, 200 μM Cl-amidine was added alternately into the wells. After 2 h of incubation at 37°C, the medium containing the reagents was removed, and the remaining cells were washed with PBS followed by fixation with 4% paraformaldehyde for 15 min. Thereafter, immunofluorescent staining for citrullinated histone 3 was carried out followed by mounting with the DAPI-containing solution. Representative photos (A). Red, citrullinated histone 3; Blue: DNA (original magnification: ×400). Quantification of NET formation (B). NET formation was quantified by counting the citrullinated histone 3-positive cells per × 100 power field of view. Data from five random fields of view (×100) were subjected to quantitative analysis. **p < 0.01 in Mann–Whitney U-test.
Establishment of Mouse Models with MPO-ANCA Production
In our earlier study, WKY rats were employed to establish an animal model of MPO-ANCA-associated vasculitis (5). In this study, we attempted to establish novel mouse models of MPO-ANCA-associated vasculitis according to the protocol for the rat model. For this purpose, BALB/c, NZW, B6/N, B6/J, and DBA mice (n = 5/strain) were given i.p. injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day) for 4 weeks (Figure 2A). The serum titers of MPO-ANCA at day 28 were 100.4 ± 12.0 ng/ml in BALB/c, 96.1 ± 12.8 ng/ml in NZW, 41.3 ± 0.90 ng/ml in B6/N, 31.6 ± 5.79 ng/ml in B6/J, and 32.0 ± 4.06 ng/ml in DBA mice (Figure 2B). Contrary to the rat model, no vasculitic lesion was observed in the lungs and kidneys of all mouse strains examined. Correspondingly, renal dysfunction was not detected in the urine and blood samples. Based on these findings, we employed BALB/c mice to construct the mouse model with MPO-ANCA production. The serum MPO-ANCA titer at day 14 was 79.0 ± 5.70 ng/ml in the BALB/c model. MPO-ANCA was not detected in the vehicle-injected BALB/c mice.
Figure 2. Establishment of mouse models with MPO-ANCA production. Experimental protocol (A). BALB/c, NZW, B6/N, B6/J, and DBA mice (14-week-old female) were given i.p. injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day) for 4 weeks (n = 5/strain, p.o.: Per Os). Mouse urine was collected during the last 24 h using metabolic cages, and then hematuria was assessed by dipsticks. Blood samples were obtained at days 14 and 28, and then the concentrations of BUN and Cr were determined. The lungs, kidneys, and peritoneal tissues were obtained at day 28. Serum titers of MPO-ANCA determined by ELISA were shown with the results of the urinalysis and concentrations of Cr in the serum (B). The normal limit of serum Cr level is 0.4 mg/dl.
Effect of PAD Inhibitor on Citrullination In Vivo
BALB/c mice (14-week-old female) were given i.p. injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day) for 2 weeks. These mice were divided into two groups. The first group was given daily i.p. injection of PBS (200 μl/day) (n = 13) and the other group with daily i.p. injection of Cl-amidine (0.3 mg/200 μl PBS/day) (n = 7) (Figure 3A). At day 14, the peritoneal tissues were subjected to immunohistochemistry for citrullinated histone 3 for the evaluation of NET formation in vivo. As a result, the rate of citrullinated histone 3-positive cells in polymorphonuclear cells was significantly reduced in the Cl-amidine-treated mice in comparison with the vehicle-injected control mice (38% reduction) (Figure 3B).
Figure 3. Effect of Cl-amidine on citrullination and MPO-ANCA production in vivo. Experimental protocol (A). BALB/c mice (14-week-old female) were given i.p. injection of PMA (50 ng at days 0 and 7) and oral PTU (2.5 mg/day) for 2 weeks (p.o.: Per Os). These mice were divided into two groups. The first group of mice was given daily i.p. injection of PBS (200 μl/day) (n = 13). The other group was given daily i.p. injection of Cl-amidine (0.3 mg/200 μl PBS/day) (n = 7). Mouse urine was collected during the last 24 h using metabolic cages. Blood and tissue samples were obtained at day 14. NET formation in peritoneal tissues (B). The formalin-fixed paraffin-embedded sections of peritoneal tissues were subjected to immunohistochemistry for citrullinated histone 3. Representative photos among five random fields of view (×100) were shown. NET induction was quantified by calculating the rate of citrullinated histone 3-positive cells in polymorphonuclear cells in the five random fields of view. *p < 0.05 in Mann–Whitney U-test. Serum titers of MPO-ANCA determined by ELISA (C). **p < 0.01 in Mann–Whitney U-test.
Effect of PAD Inhibitor on MPO-ANCA Production In Vivo
The serum titers of MPO-ANCA in the Cl-amidine-treated mice (32.3 ± 31.0 ng/ml) were significantly lower than the vehicle-injected control mice (132.1 ± 41.6 ng/ml) (Figure 3C). The collective findings clearly indicate that NET formation is inhibited by the pan-PAD inhibitor, Cl-amidine, both in vitro and in vivo, and that MPO-ANCA production is suppressed by Cl-amidine in vivo.
The PMA-stimulated neutrophils extrude decondensated DNA, which forms extracellular web-like structures decorated with bactericidal proteins (7). Since this substance, called NETs, can bind and kill bacteria, NET formation is regarded as an important event in innate immunity. Chronic granulomatous disease (CGD) patients who cannot generate NETs are susceptible to diverse bacteria and fungi indeed, and it was shown that restoration of NET formation in CGD resulted in resistance to such infections (28). Currently, it is considered that NET appears to be a form of innate response that binds microorganisms, prevents them from spreading, and ensures a high local concentration of antimicrobial agents derived from neutrophils (29).
The PMA-stimulated neutrophils undergo cell death with NET formation (8). Since the characteristics of cell death resembled neither typical necrosis nor apoptosis, Steinberg et al. coined NETosis for the neutrophil death with NET formation (30). However, Clark et al. have demonstrated that neutrophils do not necessarily undergo cell death after NET formation (31). It has been shown that NET formation can occur with preservation of neutrophilic functions, including phagocytosis and chemotaxis (10, 11). This phenomenon termed vital NETosis (9). On the contrary, aforementioned dying NETosis has been called suicidal NETosis.
Although NETs play an essential role in the innate immunity, some harmful aspects of NETs have been demonstrated (32, 33). They not only have direct cytotoxic and thrombotic effects on vascular endothelium (12–14), but NETs are also associated with pathogenic autoantibody production (5, 17). For example, impairment of NET degradation potential (low activity of DNase I) in the serum is present in 30–40% of patients with SLE and is suggested to lead the production of anti-DNA antibodies, which are related to disease severity (17). In another case, morphologically abnormal and DNase I-resistant NETs are generated by the anti-thyroid drug, PTU, and then MPO in the NETs seems to be recognized by the immune system resulting in the production of MPO-ANCA in rats administered with PTU (5). It has been shown that a part of PTU is metabolized by MPO. Simultaneously, conformational alteration of MPO could be induced by PTU (34), which could result in the tolerance break to MPO.
In the present study, we established mouse models with MPO-ANCA production. We treated five strains of mouse with PMA and PTU corresponding to the previously established protocol for the rat model of MPO-ANCA-associated vasculitis. Interestingly, there was a strain-dependency in the response to produce MPO-ANCA in mouse. Although the precise mechanism of the strain-dependency has to be determined in future studies, the Th2 phenotype of BALB/c (35) and autoimmune-prone genetic background of NZW (36) may be associated with the susceptibility to produce autoantibodies. In addition, no vasculitic lesion was observed in the mouse models with MPO-ANCA production, whereas WKY rats with MPO-ANCA developed pulmonary capillaritis and glomerulonephritis (5). Species-dependency may be present in the development of PMA plus PTU-induced MPO-ANCA-associated vasculitis. Nonetheless, we employed BALB/c mice to construct in vivo models of MPO-ANCA production.
Neeli et al. first demonstrated that PAD4-dependent histone deimination occurred in activated neutrophils under inflammatory conditions (37). Since PAD4-deficient neutrophils did not generate NETs in response to PMA, PAD4 plays a pivotal role in the NET formation (23). Correspondingly, inhibition of PAD4 using the pan-PAD inhibitor, Cl-amidine, prevented citrullination of histone 3 and significantly reduced NET release from HL60 cells, which were differentiated into mature neutrophils, in response to Ca2+ ionophore or Shigella flexneri exposure (24). In addition, Cl-amidine has been shown to suppress NET formation in lupus-prone mice (27). It has been shown that Cl-amidine can modify the cysteine of PAD and then inactivate it irreversibly (38). Based on these findings, we conducted in vitro and in vivo experiments to inhibit citrullination/NET formation using Cl-amidine as a pan-PAD inhibitor. The present study reproduced and extended the results of previous reports that investigated Cl-amidine both in vitro and in vivo and demonstrated that MPO-ANCA production was suppressed by Cl-amidine in vivo. These findings suggest that excessive formation of NETs may be implicated in MPO-ANCA production in vivo. In order to demonstrate the direct implication of PAD4-dependent NET formation in MPO-ANCA production, further studies using PAD4-deficient mice should be designed.
One limitation of this study is the lack of quantification of released NETs, which can be usually detected as MPO-DNA complexes in the serum. However, it has been shown that the PMA plus PTU-induced NETs hardly converted into soluble form (5). Thus, there is no better methodology to evaluate NETs in the murine model than the immunohistochemistry for citrullinated histone 3.
No vasculitic phenotype was observed in the PMA plus PTU-induced mouse models with MPO-ANCA production. Therefore, we could not examine the effect of PAD inhibitors on MPO-ANCA-associated vasculitis in this model, which is another limitation of this study. It should be determined whether increased doses of PMA/PTU and/or longer duration could induce vasculitis in the mouse models in future studies.
It has been shown that MPO-ANCA is the major pathogenic factor in MPO-ANCA-associated vasculitis (2, 3). Thus, it is expected that PAD inhibitors, which can suppress the production of the pathogenic autoantibody, would be applied for the treatment of patients with MPO-ANCA-associated vasculitis. Preceding studies have demonstrated the protective effects of PAD inhibitors on the models of SLE (27) and other NET-related diseases, including multiple sclerosis (39), collagen-induced arthritis (40), and inflammatory bowel disease (41). Although further studies are needed to clarify their safety and effectiveness, PAD inhibitors are potential candidates as novel therapeutic agents for various NET-related diseases, including MPO-ANCA-associated vasculitis.
YK, HS, FH, and AM performed the experiments. YK, DN, SM, SN, UT, TA, and AI analyzed and discussed the data. YK, DN, UT, and AI designed the research. YK, UT, and AI wrote the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The authors would like to thank Ms. Makiko Miwa for the technical assistance. This study was supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan [26293082 (AI)], Ministry of Health, Labour and Welfare of Japan [Research on Rare and Intractable Vasculitis (AI)], Japan Agency for Medical Research and Development [15ek0109104 and 15ek0109121 (AI)], and Akiyama Life Science Foundation (AI).
The Supplementary Material for this article can be found online at https://www.frontiersin.org/article/10.3389/fimmu.2016.00227
1. Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F, et al. 2012 revised international chapel hill consensus conference nomenclature of vasculitides. Arthritis Rheum (2013) 65:1–11. doi: 10.1002/art.37715
5. Nakazawa D, Tomaru U, Suzuki A, Masuda S, Hasegawa R, Kobayashi T, et al. Abnormal conformation and impaired degradation of propylthiouracil-induced neutrophil extracellular traps: implications of disordered neutrophil extracellular traps in a rat model of myeloperoxidase antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum (2012) 64:3779–87. doi:10.1002/art.34619
6. Sangaletti S, Tripodo C, Chiodoni C, Guarnotta C, Cappetti B, Casalini P, et al. Neutrophil extracellular traps mediate transfer of cytoplasmic neutrophil antigens to myeloid dendritic cells toward ANCA induction and associated autoimmunity. Blood (2012) 120:3007–18. doi:10.1182/blood-2012-03-416156
10. Pilsczek FH, Salina D, Poon KK, Fahey C, Yipp BG, Sibley CD, et al. A novel mechanism of rapid nuclear neutrophil extracellular trap formation in response to Staphylococcus aureus. J Immunol (2010) 185:7413–25. doi:10.4049/jimmunol.1000675
11. Yipp BG, Petri B, Salina D, Jenne CN, Scott BN, Zbytnuik LD, et al. Infection-induced NETosis is a dynamic process involving neutrophil multitasking in vivo. Nat Med (2012) 18:1386–93. doi:10.1038/nm.2847
13. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD Jr, et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A (2010) 107:15880–5. doi:10.1073/pnas.1005743107
17. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A (2010) 107:9813–8. doi:10.1073/pnas.0909927107
18. Yan J, Meng X, Wancket LM, Lintner K, Nelin LD, Chen B, et al. Glutathione reductase facilitates host defense by sustaining phagocytic oxidative burst and promoting the development of neutrophil extracellular traps. J Immunol (2012) 188:2316–27. doi:10.4049/jimmunol.1102683
19. Hakkim A, Fuchs TA, Martinez NE, Hess S, Prinz H, Zychlinsky A, et al. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol (2011) 7:75–7. doi:10.1038/nchembio.496
20. Desai J, Kumar SV, Mulay SR, Konrad L, Romoli S, Schauer C, et al. PMA and crystal-induced neutrophil extracellular trap formation involves RIPK1-RIPK3-MLKL signaling. Eur J Immunol (2016) 46:223–9. doi:10.1002/eji.201545605
23. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y. PAD4 is essential for antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med (2010) 207:1853–62. doi:10.1084/jem.20100239
24. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, et al. Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell Biol (2009) 184:205–13. doi:10.1083/jcb.200806072
25. Nakazawa D, Tomaru U, Yamamoto C, Jodo S, Ishizu A. Abundant neutrophil extracellular traps in thrombus of patient with microscopic polyangiitis. Front Immunol (2012) 3:333. doi:10.3389/fimmu.2012.00333
26. Imamoto T, Nakazawa D, Shida H, Suzuki A, Otsuka N, Tomaru U, et al. Possible linkage between microscopic polyangiitis and thrombosis via neutrophil extracellular traps. Clin Exp Rheumatol (2014) 32:149–50.
27. Knight JS, Zhao W, Luo W, Subramanian V, O’dell AA, Yalavarthi S, et al. Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus. J Clin Invest (2013) 123:2981–93. doi:10.1172/JCI67390
28. Bianchi M, Hakkim A, Brinkmann V, Siler U, Seger RA, Zychlinsky A, et al. Restoration of NET formation by gene therapy in CGD controls aspergillosis. Blood (2009) 114:2619–22. doi:10.1182/blood-2009-05-221606
31. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, et al. Platelet TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med (2007) 13:463–9. doi:10.1038/nm1565
33. Grayson PC, Kaplan MJ. At the bench: neutrophil extracellular traps (NETs) highlight novel aspects of innate immune system involvement in autoimmune diseases. J Leukoc Biol (2016) 99:253–64. doi:10.1189/jlb.5BT0615-247R
34. Lee E, Hirouchi M, Hosokawa M, Sayo H, Kohno M, Kariya K. Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem Pharmacol (1988) 37:2151–3. doi:10.1016/0006-2952(88)90574-6
38. Luo Y, Arita K, Bhatia M, Knuckley B, Lee YH, Stallcup MR, et al. Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry (2006) 45:11727–36. doi:10.1021/bi061180d
39. Moscarello MA, Lei H, Mastronardi FG, Winer S, Tsui H, Li Z, et al. Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis. Dis Model Mech (2013) 6:467–78. doi:10.1242/dmm.010520
40. Willis VC, Gizinski AM, Banda NK, Causey CP, Knuckley B, Cordova KN, et al. N-alpha-benzoyl-N5-(2-chloro-1-iminoethyl)-L-ornithine amide, a protein arginine deiminase inhibitor, reduces the severity of murine collagen-induced arthritis. J Immunol (2011) 186:4396–404. doi:10.4049/jimmunol.1001620
41. Chumanevich AA, Causey CP, Knuckley BA, Jones JE, Poudyal D, Chumanevich AP, et al. Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor. Am J Physiol Gastrointest Liver Physiol (2011) 300:G929–38. doi:10.1152/ajpgi.00435.2010
Keywords: MPO-ANCA-associated vasculitis, MPO-ANCA, neutrophil extracellular trap, peptidylarginine deiminase 4, peptidylarginine deiminase inhibitor
Citation: Kusunoki Y, Nakazawa D, Shida H, Hattanda F, Miyoshi A, Masuda S, Nishio S, Tomaru U, Atsumi T and Ishizu A (2016) Peptidylarginine Deiminase Inhibitor Suppresses Neutrophil Extracellular Trap Formation and MPO-ANCA Production. Front. Immunol. 7:227. doi: 10.3389/fimmu.2016.00227
Received: 17 March 2016; Accepted: 26 May 2016;
Published: 08 June 2016
Edited by:Marko Radic, University of Tennessee, USA
Reviewed by:Paul Proost, University of Leuven, Belgium
Angelo A. Manfredi, Vita Salute San Raffaele University, Italy
Huw Lewis, GlaxoSmithKline, UK
Copyright: © 2016 Kusunoki, Nakazawa, Shida, Hattanda, Miyoshi, Masuda, Nishio, Tomaru, Atsumi and Ishizu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Akihiro Ishizu, email@example.com